-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Management of Waldenström Macroglobulinemia in 2020

Program: Education Program
Session: Monoclonal Gammopathies of Determined Significance
Hematology Disease Topics & Pathways:
Biological, Diseases, Therapies, B-Cell Lymphoma, Lymphoid Malignancies, Clinically relevant, TKI
Sunday, December 6, 2020, 1:55 PM-2:00 PM

Jorge J. Castillo, MD

Dana Farber Cancer Institute, Boston, MA

Disclosures: Castillo: Abbvie: Research Funding; Pharmacyclics: Consultancy, Research Funding; TG Therapeutics: Research Funding; Kymera: Consultancy; Janssen: Consultancy, Research Funding; Beigene: Consultancy, Research Funding.

OffLabel Disclosure: Acalabrutinib, venetoclax and zanubrutinib are not approved by the FDA for Waldenstrom macrolgobulinemia.

See more of: Monoclonal Gammopathies of Determined Significance
See more of: Education Program
<< Previous Presentation | Next Presentation >>